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Abstract
Background: The variety and limitations of current laboratory methods for estimating HIV-incidence has driven attempts to
improve and standardize the performance of serological ‘Tests for Recent HIV-Infections’ (TRI). Primary and follow-up HIV-1
positive plasma samples from individuals with well-defined dates of infection collected as part of the German Seroconverter
Cohort provided specimens highly suitable for use in comparing the performance of three TRIs: the AWARETM BEDTM EIA
HIV-1 Incidence test (BED-CEIA), Genetic systems HIV-1/HIV-2 Plus O EIA antibody avidity-based assay (BioRad Avidity) and
SediaTM HIV-1 LAg Avidity EIA (LAg Avidity).
Methods: The evaluation panel included 180 specimens: 44 from antiretroviral (ARV)-naı̈ve individuals with recently
acquired HIV-infection (#130 days; 25 B and 19 non-B subtypes) and 136 from long-term (.12 months) infected individuals
[101 ARV-naı̈ve subtype B, 16 non-B subtypes, 14 ARV-treated individuals, 5 slow progressors (SLP)].
Results: For long-term infected, ARV-naı̈ve individuals the false recent rates (FRR) of both the BioRad and LAg Avidity assays
were 2% (2/101 for subtype B) and 6% (1/16 for subtype ‘non-B’), while the FRR of the BED-CEIA was 7% (7/101 for subtype
B) and 25% (4/16 for subtype ‘non-B’) (all p.0.05). Misclassification of ARV-treated individuals and SLP was rare by LAg (1/
14, 0/5) and BioRad Avidity assays (2/14, 1/5) but more frequent by BED-CEIA (5/14, 3/5). Among recently-infected
individuals (subtype B), 60% (15/25) were correctly classified by BED-CEIA, 88% (22/25) by BioRad Avidity and significantly
fewer by LAg (48%, 12/25) compared to BioRad Avidity (p= 0.005) with a higher true-recency rate among non-B infections
for all assays.
Conclusions: This study using well-characterized specimens demonstrated lower FRRs for both avidity methods than with
the BED-CEIA. For recently infected individuals the BioRad Avidity assay was shown to give the most accurate results.
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Introduction
Monitoring the HIV-epidemic and identifying populations
amongst whom HIV is spreading is critical for public health
services, allowing them to identify groups at risk and target
preventive interventions effectively. Reliable methods to estimate
HIV incidence in cross-sectional surveys are therefore crucially
important. Over the past fifteen years, a variety of serological
assays able to differentiate recently acquired from established
HIV-1 infections have been developed [1–4]. Most of these ‘Tests
for Recent (HIV) Infections’ (TRI) are based on the fact that
evolution and maturation of HIV-1 specific antibodies occur
within the first two years after seroconversion [5,6]. Accordingly,
incidence assays differentiate between recently acquired and long-
term infections based on i) the increase in antibody titer [7–9], ii)
the increase in the proportion of HIV-1 specific immunoglobulin
G (IgG) antibodies relative to total IgG [10], iii) the increase of
antibody avidity [11–15] or iv) a combination of these markers
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[6,16–20]. Classification of individuals as either recently or long-
term infected is finally determined by the quantitative output
relative to a defined cut off.
For many years, the BED-capture-enzyme immunoassay (BED-
CEIA) [10] was the most commonly used incidence assay for HIV-
surveillance, both in Germany and worldwide [21–25]. However,
reports of substantial over-estimation of incidence due to the
misclassification of established infections as recently acquired
infections dampened the acceptance and use of the BED-CEIA
[26,27]. Although formula-based adjustment for BED-CEIA
estimates have been proposed [28–30], these limitations prompted
the search for novel assays with improved accuracy.
In 2010 the performance of a new avidity-based assay using a
modified version of the BioRad HIV-1/2 Plus O protocol (BioRad
Avidity) was presented by Masciotra et al. 2010 [13] showing
improvements in test accuracy [31,32].
Furthermore, in 2010 two new avidity-based assays using multi-
subtype gp41 recombinant protein in a two-well and a novel
single-well format were described, the latter of which becoming
commercially available as Sedia TM HIV-1 LAg Avidity EIA
(LAg Avidity) [14,33].
However, currently available incidence assays continue to be
challenged by the variability of immune responses among infected
persons. One of the main problems is the identification of ‘false
recent’ infections as a result of low HIV-antibody titer or low
binding affinity. This type of misclassification occurred particularly
for long-term infected individuals on antiretroviral (ARV) treat-
ment, individuals with advanced AIDS progression and for elite
controllers [4,31,34–36]. Additionally, the accuracy of the assays
was found to vary depending on the viral subtype [37–39].
The ‘Consortium for the Evaluation and Performance of HIV
Incidence Assays’ (CEPHIA) [40], a collaboration of international
public health professionals and scientists founded by the Bill &
Melinda Gates Foundation, is currently evaluating of the most
commonly used incidence assays (‘candidate’ assays) [41] in order
to identify a test that is quick, inexpensive, easy-to-use, valid,
robust, precise and provides a reliable standard method or
algorithm for estimating incidence [40]. Test performance focuses
on two interacting test parameters that jointly specify the test
characteristics: the mean duration of recency (MDR) as the
average time that an individual is classified as recently infected
(proposed to be 4–12 months) and the false recent rate (FRR) -
characterizing the frequency of misclassified long-term infections
as recent infection - which should be ,2% [31,36,41]. To allow
comparisons of test evaluations CEPHIA established a specimen
repository comprising of recent and long-term (.12 months)
infection specimens, as well as ‘challenge specimens’ that include
samples from elite controllers, ARV-treated/suppressed individu-
als and non-B subtypes of HIV-1 [42,43].
The German HIV-1 Seroconverter study - a national multi-
center long-term observational open cohort study running since
1997 - comprises longitudinal HIV-1 positive plasma specimens
from individuals with well-defined periods of infection. These
specimens, precisely characterized in terms of duration of infection
and detailed course of ARV-treatment, offer the opportunity to
evaluate the performance of selected ‘candidate’ assays. In the
present study, the performance of the BioRad Avidity and the
commercially available LAg Avidity assays was compared to that




Signed informed consent is obtained from all subjects prior to
enrolment. The study is approved by the ethical committee of
Charité- Universitätsmedizin Berlin, Germany.
Evaluation Panel
All specimens included in the evaluation panel of the present
study were primary or follow- up samples collected within the
German HIV-1 Seroconverter (SC) Cohort [44]. The dates of
infection are well-defined by the following documented laboratory
test results:
(1) Detectable HIV-RNA plus negative ELISA OR a reactive
ELISA plus negative or indeterminate immunoblot as evidence of
an ongoing but incomplete seroconversion (‘acute SC’); comple-
tion of seroconversion is subsequently confirmed during follow-up
within six months. For these patients the date of infection is
defined as the blood sampling date for the first reactive test. (2) A
last negative and a first positive documented HIV-antibody test
result (‘documented SC’) are available. The date of infection is
calculated as the arithmetic mean of both test dates. For inclusion
into the present work only documented SC were included for
whom the negative and positive HIV-antibody test results were
available with a maximal time interval of 90 days.
The evaluation panel comprised sets of ‘recent infections’, ‘long-
term infections’ and a ‘challenge specimens’. All specimens chosen
for the ‘recent infections’ set were immunoblot positive and had
been collected $14 days and #130 days after the defined date of
infection. Samples included in the ‘long-term infection’ and
‘challenge specimen’ sets were selected from collections $52 weeks
after the defined date of infection. To avoid individual-specific bias
in assay performance only one specimen per HIV-positive patient
was analyzed. In total, the evaluation panel was made up of 180
cross-sectional samples. All specimens included in the ‘recent’ set
(n = 44; 25 B subtypes and 19 non-B subtypes) and the ‘long-term
infections’ set (n = 117; 101 B subtypes and 16 non-B subtypes)
were collected from ARV-naı̈ve individuals.
The ‘challenge specimens’ set (n = 19) comprised a subset of 14
plasma samples from ARV-treated individuals with either CDC
status A or B and CD4 cell counts .350 cells/ml (n = 8) or with
advanced disease progression as characterized by: CDC status C
and CD4 cell counts #350 cells/ml (n = 6). A second subset of the
‘challenge specimens’ consisted of five plasma samples from ARV-
naı̈ve individuals with slow disease progression, defined by CD4
cell counts (at least 3 available) that did not fall below 500 cells/ml
for at least 8 years of infection (Table 1).
The ‘recent infections’ set was mainly selected from those ‘acute
SC’ individuals with the most precise dates of infection: 100% (25/
25) in the subset of subtype B samples and 95% (18/19) in the non-
B samples. In the ‘long-term infections’ set 99% (100/101) and
88% (14/16) of follow-up specimen were obtained from ‘acute SC’
for the subtype B and non-B subsets, respectively. The ‘challenge
specimens’ set was composed of 57% (8/14) and 40% (2/5) ‘acute
SC’ (long-term infected ARV-treated individuals and slow
progressors, respectively) (table 1). The FRR was calculated from
the number of specimen falsely classified as ‘recent’ within the
‘long-term infections’ or ‘challenge specimens’ sets.
Within the German SC Cohort, patient characteristics such as
demographic (including sex and age at enrolment), clinical status
(including CDC-status and current ARV regimens) and laboratory
data (including viral load, CD4+ and CD8+ cell counts) are
provided with the samples. Longitudinal plasma samples and
clinical information are collected in yearly follow-ups. Signed
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informed consent is obtained from all subjects prior to enrolment.
The study is approved by the ethical committee of Charité-
Universitätsmedizin Berlin, Germany.
The REGA HIV-1 subtyping tool [42,43,45] was used to
subtype HIV-1 based on the pol population sequences determined
during genotypic resistance monitoring (Viroseq HIV-1 Genotyp-
ing System version 2, Abbott, Wiesbaden, Germany).
Methodology
All specimens were analyzed using the three HIV-1 incidence
assays BED-CEIA, BioRad Avidity and LAg Avidity according to
the recommended protocols.
The commercially available BED-CEIA (AWARETM BEDTM
EIA; Calypte Biomedical Corporation, Lake Oswego, OR, USA)
is a single well incidence assay. The proportion of HIV-1 specific
anti-gp41-IgG compared to total IgG in the sample is determined
by a calibrator-normalized OD value (ODn). ODn values below
the cut off of 0.8 are classified as recent infections. The MDR as
described in the manufacturers instructions is 155 days.
For the BioRad Avidity assay modifications of the commercial
Genetic Systems HIV-1/HIV-2 Plus O EIA (Bio-Rad Laborato-
ries, Redmond, WA, USA) were made. In the two-well avidity
assay specimens diluted 1:10 are initially incubated 30 minutes at
4uC and were then treated in parallel with either 0.1 M DEA
dissociation agent or wash buffer. An avidity index (AI) is
calculated from both OD values (OD (DEA)/OD (wash buffer)
x100) for each sample. Specimens with an AI below 30% are
classified as ‘recent infections’ [13]. One recent and prevalent
sample with known duration of infection each (three and 58 weeks
of infection, respectively) are used as internal test controls. The
MDR according to Masciotra and Owen (personal communica-
tion) is 220 days for infections with subtype B or 209 days for
infections with non-B subtypes.
The LAg Avidity (SediaTM HIV-1 LAg Avidity EIA; Sedia
Biosciences Corporation, Portland, OR, USA) is a new commer-
cially available antibody avidity-based single well incidence assay.
Patients antibodies are allowed to bind to recombinant proteins
containing the HIV-1 immune dominant region (IDR) of gp41
(coating antigen). Using 0.1 M citrate buffer as a dissociation
agent, the antibody avidity is measured as an ODn value adjusted
by calibrator and controls. According to the 2013 manual
specimens with an ODn value below 1.5 are classified as ‘recent’
and the respective MDR is 130 days.
To identify significant differences between the median quanti-
tative assay outputs for specimens from the ‘recent’ and ‘long-term
infections’ set, statistical analyses were carried out using the non-
parametric Mann-Whitney-U test (IBM SPSS Statistics 20; SPSS
Inc., Chicago, Illinois, USA). The independence of categorical
variables was analyzed using the two-tailed Fisher’s exact test that
can be applied to small sample sizes (GraphPad QuickCalcs:
http://www.graphpad.com/quickcalcs/contingency1.cfm). Only
p-values below 0.05 were considered to be significant.
Results
Characteristics of the Evaluation Panel
Characteristics of the ‘recent’, ‘long-term’ and ‘challenge’ sets
used for evaluation are shown in Table 1.
Among the subset of ‘recent HIV-1 non-B infections’, HIV
subtypes A1 (n = 5), C (n = 4), CRF01_AE (n = 3), CRF02_AG
(n = 4), D (n = 1) and F1 (n = 2) were identified. Subtypes A1
(n = 3), C (n = 4), CRF01_AE (n = 1), CRF02_AG (n = 5), D (n = 1)
and G (n = 2) were identified in the ‘long-term non-B infections’
subset. Slow progressors and ARV-treated individuals were all
infected with subtype B, although no sequence was available for
one patient and the subtype remained unknown (Table 1).
The median BED-CEIA ODn value was significant lower in
‘recent infections’ set than in the ‘long-term infections’ set (0.3
(IQR 0.1–0.9) vs. 2.7 (IQR 1.9–3.6); p,0.001; Figure 1a). The
median BioRad AI was also significantly lower for ‘recent
infections’ than for ‘long-term infections’ (6.2% (IQR 4.6–19) vs.
100% (IQR 86–100); p,0.001; Figure 1b). In addition, the
median LAg Avidity ODn value was significantly lower in the
‘recent infections’ set than in the ‘long-term infections’ set (1.3
(IQR 0.5–2.2) vs. 5.1 (IQR 4.4–5.6); p,0.001; Figure 1c).
Comparison of True and False Recent Rates between the
Three Incidence Tests
Among individuals with recently acquired subtype B infection
60% (15/25) were correctly classified by BED-CEIA, 88% (22/25)
by BioRad Avidity and 48% (12/25) by LAg Avidity. The
proportion of correctly classified recent samples was significantly
higher by BioRad Avidity compared to LAg Avidity (p,0.01) and
tended to be higher for BED-CIA (p= 0.05) whereas the
differences between BED-CEIA and LAg Avidity (p= 0.57) were
less pronounced. Correct recency rates among individuals with
HIV-1 ‘non-B’ infections were: 84% (16/19) by BED-CEIA, 89%
(17/19) by BioRad Avidity and 63% (12/19) by LAg Avidity with
none of the differences being statistically significant (all p.0.05)
(Figure 2a).
The FRRs in the subsets of ‘long-term infections’ were 7%
(subtype B) and 25% (‘non-B’) for the BED-CEIA and 2%
(subtype B) and 6% (‘non-B’) for both avidity assays BioRad and
LAg Avidity (Figure 2b). Although misclassification of ‘challenge
specimens’ occurred at most once using the LAg Avidity (1/8, 1/6,
0/5) and BioRad Avidity (1/8, 1/6, 1/5) assays within the subsets
of long-term infected, ARV-treated individuals (CD4 cell counts #
or .350 cells/ml) and slow progressors, it occurred more
frequently by BED-CEIA (2/8, 3/6, 3/5). The overall FRRs
(‘long-term infections’ plus ‘challenge specimen’) for BED-CEIA
(14%), BioRad (4.4%) and LAg Avidity (3.7%) were significantly
higher for BED-CEIA compared to BioRad (p = 0.01) and LAg
Avidity (p = 0.005), but pairwise comparisons between tests for all
subsets of ‘long-term infections’ (Figure 1b) and ‘challenge
specimens’ (Figure 2c) did not reach statistical significance (all
p.0.05).
Misclassification of samples by the three incidence
assays. Some of the samples misclassified by one of the three
assays were also misclassified by one or both of the other two
incidence tests (Figure 3). In particular, all samples misclassified by
BED-CEIA in the ‘recent infections’ set (n = 13/44) were also
misclassified by LAg Avidity (18/44; intersection of n = 13
samples) and all samples classified as ‘false recent’ by LAg Avidity
in the ‘long-term’ and ‘challenge specimens’ set (n = 5/136) were
also misclassified by BED-CEIA (19/136; intersection of n = 5
samples; Figure 3B). In contrast, of the 5/44 and 13/44 ‘‘recent’’
samples misclassified by the BioRad Avidity and BED-CEIA
assays respectively, four were commonly misclassified, and of the
11/136 and 19/136 (respectively) ‘‘long-term’’ infection samples
misclassified, five were the same (Figure 3A). Similarly, the LAg
Avidity assay, with 18/44 ‘‘recent’’ and 5/136 ‘‘long-term’’
infection misclassified samples had four in common with the
BioRad Avidity assay for each set (Figure 3C).
False recent classifications within the subset of ‘long-term non-B
infections’ could be assigned to different subtypes: 2/3 for A1, 1/1
for D and 1/4 for C by BED-CEIA, as well as 1/3 for A1 and 1/1
for D by LAg Avidity. The only ‘non-B’ subtype sample giving a
false recent classification by the BioRad Avidity assay was shown
Comparison of Performance of Three Incidence Assays
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to be a subtype D isolate that was also misclassified by BED-CEIA
and LAg Avidity (data not shown).
Discussion
FRR and MDR are considered to be important parameters for
the evaluation of incidence assays [4,31,41,46]. While MDRs were
defined by the manufacturers instructions (BED-CEIA and LAg
Avidity) or provided with the protocol (BioRad Avidity) [13], the
FRR was calculated for the three incidence assays BED-CEIA,
BioRad Avidity and LAg Avidity using primary and follow-up
samples with known dates of infection selected from the German
Seroconverter Cohort.
Compared to the BED-CEIA the two antibody avidity-based
assays (LAg Avidity and BioRad Avidity) generally gave signifi-
cantly lower proportions of false recent classifications for long-term
infected individuals and therefore lower FRRs. High FRRs from
the BED-CEIA, in particular for individuals undergoing ARV
treatment, those with advanced progression to AIDS and for elite
controllers have also been described previously [47,48]. Since the
BED-CEIA is based on the proportion of HIV-specific IgG
antibodies relative to the total quantity of IgG, individuals with
viral suppression (elite controllers or ARV treated) or waning
antibodies due to advanced HIV progression (in our study CDC
status C) are at risk of being misclassified as recent. In contrast,
antibody avidity depends on the degree of antibody maturation,
Figure 1. BED-CEIA, Bio-Rad Avidity and Lag-Avidity results according to duration of infection. Samples from the evaluation panel were
analyzed using the BED capture enzyme immunoassay (A), Bio-Rad Avidity assay (B) and LAg-Avidity enzyme immunoassay (C). Respective assay cut-
offs are indicated by the black line. Data are shown for subsets of the evaluation panel.
doi:10.1371/journal.pone.0098038.g001
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which in turn is directly correlated with duration of infection [2].
Samples with decreased antibody content, as reported for
individuals with viral suppression and advanced disease, were
correctly classified more often using the avidity assays, resulting in
lower FRRs than the BED-CEIA [32,36,49]. However, factors
such as recent sample collection, viral suppression and lower
CD4+ cell counts were recently reported to be associated with false
recent classification using the LAg Avidity [50].
Likewise, high FRRs generated by BED-CEIA for individuals
with ‘non-B’ infections have been described previously and
calculating and adapting the MDR for each ‘non-B’ subtype by
generating more data was suggested [39].
In our study, the FRRs by BED-CEIA within the group of
immunosuppressed individuals (‘challenge specimens’ subset) and
the subset of ‘non-B infections’ were indeed higher compared to
both avidity assays, although the differences did not reach
significance for the respective subsets. The misclassification of
samples from subtype D infected individuals (as occurred in our
study using all three assays) was also recently reported for BioRad
and LAg Avidity assays [50,51] and was reported to be due to a
weak initial antibody response to HIV infection that is maintained
over time. However, the number of samples in the subsets of non-
B infections and the ‘challenge specimen’ set is far too small to
power statistical comparison.
In the set of ‘recent infections’, the BioRad Avidity assay
performed best for subtype B infected individuals, giving a
significantly higher true recent rate of 88% compared to the
relatively low true recent rate of LAg Avidity (48%). Based on the
previous LAg Avidity cut-off (ODn = 1.0) and MDR (141 days) as
provided by the manufacturer in 2012, an additional four samples
(134–141 days of infection, subtype B) would be included in the
‘recent infections’ set resulting in a significantly lower true recent
rate for the LAg Avidity assay (31%) compared to those for the Bio
Rad Avidity assay (86%, p= 0.0001) and BED-CEIA (62%,
p= 0.03) [52]. The re-adjustment of the LAg Avidity ODn cut-off
in 2013 (raising it from 1.0 to 1.5 based on CEPHIA evaluations)
improved the performance to give a true recent rate of 48%,
although this is still low compared to the BioRad Avidity assay.
The increase in cut-off was accompanied by a decrease in the
MDR from 141 to 130 days (4.7 to 4.3 months). This very short
MDR is further from the proposed MDR of 4–12 months [36].
For the LAg Avidity assay the ratio for correct ‘recent’
classifications in the ‘recent infections’ set was very low (48%)
while the ratio for correct classification in the ‘long-term
infections’ set was high (98%). For the BED-CEIA the correct
Figure 2. Comparison of BED-CEIA, Bio-Rad and LAg-Avidity assay results according to subtype, clinical stage and disease
progression. True recent ratios within the ‘recent infections set’ subtype B and ‘non-B’ (A). False recent ratios among long-term subtype B and ‘non-
B’ infected, ARV-naı̈ve individuals (B). Misclassification in the ‘challenge specimens’ set (C). Only significant p-values (,0.05) of pairwise comparisons
were indicated.
doi:10.1371/journal.pone.0098038.g002
Figure 3. Number of samples in the set of recent (n=44) and long-term infections (incl. ‘challenge specimens’; n =136) misclassified
by two incidence assays. Misclassified samples (A) by the BED-CEIA, BioRad Avidity and by both assays (B) by the BED-CEIA, LAg Avidity and by
both assays and (C) by BioRad Avidity, LAg Avidity and by both assays.
doi:10.1371/journal.pone.0098038.g003
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‘recent’ classifications ratio was also low with 60% and far below
published data of 82% (previously termed ‘sensitivity’, using the
terminology for individual diagnostics) [10]. In this context, it is
remarkable that the BED-CEIA and LAg Avidity assays often
misclassified the same specimens. In contrast, samples misclassified
by BioRad Avidity assay coincided less with those misclassified by
BED-CEIA and LAg Avidity. This might be due to the fact that
both the BED-CEIA and the LAg Avidity assay are based on gp41
epitopes whereas the antigens used in the BioRad Avidity assay
bind to a broader spectrum of the individuals antibodies (IgM,
IgG) and might therefore react differently. It is therefore not
recommended to use the BED-CEIA and LAg-Avidity assay
together in multi-assay algorithms [53]; the use of BioRad Avidity
in combination with BED-CEIA or Lag Avidity would be the
better choice.
Certainly, FRR is an important parameter, in particular in
countries with a low prevalence of HIV, and it is important to limit
the misclassification of long-term infections as recent. However, in
our opinion, the correct identification of recent samples with the
aim of also reducing the number of false long-term samples should
not be ignored in an effort to minimize the FRR. In Germany,
where the testing for recent infections is based on the analysis of
specimens from newly diagnosed individuals, it is of great
importance to identify those individuals with recently acquired
infection amongst the newly diagnosed to avoid underestimating
the rate of new infections as well as overestimating by a high FRR.
One limitation of our study is the relatively low number of
samples in the subsets of ‘recent infections’, of ‘non-B infections’
and of the ‘challenge specimens’. This was caused by restricting
samples to those from individuals with very well-documented
seroconversions and by the low prevalence of ‘non-B’ subtypes and
long-term non-progressors in the German SC cohort. However,
despite being limited in size, results obtained with this study agree
with previous reports and have shown significant differences
within the subset of ‘‘recent subtype B infections’’.
The tentative outcome is nevertheless an indication that among
long-term infected ARV naive individuals, both avidity assays
delivered lower FRRs than the BED-CEIA. Of the two avidity
methods, BioRad Avidity was best at identifying truly recent
infections, with a FRR similar to the LAg Avidity. However,
although the new 2013 cut-offs improved the LAg Avidity assay, it
may still be underestimated the true proportion of recent infections
in newly diagnosed individuals. To date, a thorough evaluation of
the LAg Avidity and BioRad Avidity assays for use in incidence
estimation is still pending and additional studies that include
samples with less than one year of infection should be carried out.
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